Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.
LowReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $48.00. They now have an "outperform" rating on the stock.
LowReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $48.00. They now have an "outperform" rating on the stock.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
MediumReport
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
MediumReport
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: